Y-mAbs Therapeutics always had an intriguing story. It just never did much about telling it — until now.
On Friday, the biotech filed for a $92 million IPO, and skated through what we already knew: Back-to-back venture rounds had recently pumped $80 million into the company, which is run by a group of ex-Genmab execs with rights to two key cancer drugs — naxitamab and burtamab — that target GD2 and B7-H3.
In the process, though, the biotech also unveiled some interesting facts about its wealthy backer, a partial FDA hold and the very personal tale of an endangered child whose treatment at Memorial Sloan Kettering years ago helped inspire a startup.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,900+ biopharma pros who read Endpoints News by email every day.Free Subscription